REPORT on the proposal for a regulation of the European Parliament and of the Council laying a framework for strengthening the availability and security of supply of critical medicinal products as well as the availability of, and accessibility of, medicinal products of common interest, and amending Regulation (EU) 2024/795
A10-0272/2025SANT· Laying a framework for strengthening the availability and security of supply of critical medicinal products as well as the availability of, and accessibility of, medicinal products of common interest, and amending Regulation (EU) 2024/795document ↗Filter in the vote browser →
Internal market - PrinciplesPublic healthHealth legislation and policyMedicine, diseasesPharmaceutical products and industrycompetitivenessenvironmental lawEU productionexpert group (EU)healthcare industryinvestmentmedicinal productpharmaceutical legislationsecurity of supplyshortagesupply chainProprietary medicinal products
The report sets out Parliament's position on a new law to prevent shortages of essential medicines. It wants more manufacturing of critical medicines inside the EU, faster permits for new factories, and public buying rules that reward reliable supply rather than just the lowest price. It also asks for shared EU stockpiles, a way to move medicines between countries in emergencies, and more transparency about where ingredients come from.
- New rules would favour EU-made medicines in public purchasing and speed up factory permits.
- Patients, manufacturers, hospitals and national governments would all be affected.
- Parliament's position now goes to EU governments for negotiation on the final law.